Schizophrenia Patients Don’t Take Medications Regularly Resulting
in Higher Medical Costs, UCSD Researchers Find
Despite improved drugs for schizophrenia – a
devastating mental illness that affects more than 2 million
Americans and one percent of the world’s population – a new study
shows that only 41 percent of patients take their antipsychotic
medication on a regular basis. Researchers also found that
out-patient and hospital medical costs are significantly higher in
the patients who are not regularly adherent to a prescribed drug
regimen.
Twenty-four percent of the patients are
non-adherent and 17 percent are only partially compliant to a
prescribed drug schedule, according to the study published in the
April 2004 issue of the American Journal of Psychiatry. A
surprising finding was a high percentage of schizophrenia patients –
19 percent – identified as “excess fillers.” This means that they
filled their prescriptions more frequently than prescribed.
|
 |
|
Dilip Jeste,
M.D.,and Todd Gilmer, Ph.D. |
According to the researchers from the University
of California, San Diego (UCSD) School of Medicine, the findings
point to a need for improved management of schizophrenia patients by
all members of the treatment team, including physicians,
pharmacists, family members and case management workers in community
health settings.
“Estimating the medical costs of non-adherence
might also provide an incentive for insurers to allocate resources
to improve adherence in patients with schizophrenia,” said the
study’s senior author, Dilip Jeste, M.D., UCSD professor of
psychiatry and neurosciences and the Estelle and Edgar Levi Chair in
Aging. “Hospital expenditures, for example, are more than three
times higher among those who are non-adherent than are expenditures
for patients who take their medication on schedule.”
Jeste, who is also director of the UCSD Stein
Institute on Aging and a geriatric psychiatrist with the VA San
Diego Healthcare System, noted that just as the partial- and
non-adherent group experienced excessive medical costs, so did the
excess fillers. A little more than half of the excess fillers were
individuals who received prescriptions for mutiple antipsychotic
medications.
Additional findings in the study were:
-
Both psychiatric and medical hospitalizations
were strongly related to the degree of drug adherence;
-
Older individuals were more likely to be
adherent that younger patients;
-
African-American and Latino patients were
more likely to be partially or non-adherent than Caucasians;
-
Non-adherence had a high association to
living condition, with those living independently or homeless
most likely to be non-adherent.
The study was conducted with Medi-Cal (California’s
Medicaid program) claims and eligibility data from 1998 to 2000 in
1,619 schizophrenia patients receiving services from San Diego
County Adult Mental Health Services. Analyses were based on
prescriptions filled for oral antipsychotic medications. The
researchers considered a person partially adherent or non-adherent
when a prescription was not refilled on schedule. Medi-Cal claims
were used to determine hospitalization in a given year and the total
amount paid by MediCal for inpatient care.
San Diego, with its size as the sixth largest county
in the United States, and with its diverse ethnic composition
“provides a suitable sample to investigate non-adherence. In our
study, the ethnic diversity of our subjects approximated that of the
County’s general population,” said the study’s first author, Todd
Gilmer, Ph.D., UCSD assistant professor of family and preventive
medicine.
More Detailed Information on the Study’s
Findings:
Psychiatric hospitalization was strongly related
to the degree of drug adherence, with those considered non-adherent
two and one-half times more likely to be hospitalized than those who
were adherent. Individuals who were partially adherent or excess
filler were 80 percent more likely to be hospitalized. Similar
increases were found in hospitalization for medical
(non-psychiatric) conditions.
Unlike previous investigations of drug adherence
in schizophrenia patients, the UCSD team found significant
associations between treatment adherence, age and ethnicity. The
likelihood of adhering to an antipsychotic medication generally
increased with age. For example, adherence in those younger than 30
years was approximately 36 percent as compared to 48 percent in
those age 60 years and above. African-Americans and Latinos had a
lower probability of being adherent than Caucasians. While 43
percent of non-Latino whites adhered to their prescription regimen,
the team said the adherence among African-Americans was 35 percent
and 37 percent among Latinos.
“While previous studies have shown that
African-Americans were significantly less likely to be adherent to
their antipsychotic medication, the low rate among Latinos is a new
finding,” Gilmer said.
He noted that adherence of any particular ethnic
group is likely to be affected by a unique combination of factors
including cultural beliefs and expectations, as well as access to
care and physiological differences in therapeutic response to
treatment.
The researchers found that non-adherence had a
high association to living situation. About one-half of the patients
in the study lived independently, 25 percent resided in assisted
living facilities, 19 percent lived with family members, and 5
percent were homeless. The highest compliance was among those living
with family members or in an assisted living facility. Less adherent
were individuals living independently, or those designated as
homeless.
“Of course, those living independently or
homeless are least likely to receive medication supervision, to have
the support of family members, and to have access to outpatient
care,” Jeste said.
Taken together, all the findings indicate a need
for increased interventions to help schizophrenia patients improve
medication adherence, the researchers said.
“Our findings argue for new approaches to improve
the effectiveness of health services delivered to the mentally ill
through the existing network of agencies and providers. They also
suggest targeting subgroups for specific improvement strategies to
protect high-risk patients with schizophrenia,” the investigators
said in their study.
The research was supported by grants from the
National Institute of Mental Health and the U.S. Department of
Veterans Affairs.
Additional authors of the paper were Piedad
Garcia, Ed.D., director, Psychosocial Services, San Diego County
Mental Health System; Christian R. Dolder, Pharm.D., Wingate
University, Durham, North Carolina; Jonathan P. Lacro, Pharm.D. and
Laurie Lindamer, Ph.D., UCSD Department of Psychiatry; and David P.
Folsom, M.D., UCSD Departments of Psychiatry and Family and
Preventive Medicine.